AstraZeneca Advances In Early Stage Lung Cancer With Imfinzi And Tagrisso
Pursuing Leaders With Double Neoadjuvant/Adjuvant Approach
Executive Summary
AstraZeneca’s Imfinzi is playing catch-up to other PD1/L1 targeting agents in neoadjuvant/adjuvant NSCLC with new data from AEGEAN, but new survival data for Tagrisso from ADAURA consolidate its dominance in early-stage EGFR positive disease.
You may also be interested in...
What Opdivo Has To Beat In Perioperative Lung Cancer
A positive showing by Bristol Myers Squibb’s checkpoint inhibitor Opdivo in non-small cell lung cancer could broaden its use, though much depends on the magnitude of the hit.
AstraZeneca’s Imfinzi Scores Neoadjuvant/Adjuvant NSCLC Two-fer At AACR
The PD-L1 inhibitor showed efficacy in the neoadjuvant/adjuvant setting, where Merck is developing Keytruda as well. BMS’s Opdivo was the first to win approval in neoadjuvant NSCLC.
AstraZeneca Looks To Muscle In On BMS-Dominated Neoadjuvant NSCLC Setting
Without disclosing data, the company reported positive pathological complete response data from the AEGEAN study of its PD-L1 inhibitor Imfinzi in neoadjuvant NSCLC, where BMS’s Opdivo won approval in March.